Skip to content
Search

Latest Stories

Regulator strikes out two-year requirement as registered pharmacist for IP training in Northern Ireland

The Council of the Pharmaceutical Society NI (PSNI) to remove the two-year requirement as a registered pharmacist to have an Independent Prescriber (IP) annotation on the pharmacy register in Northern Ireland.

It has further endorsed that the two-year requirement for entry onto stand-alone pharmacist independent prescribing courses be removed and replaced with an assessment before admission, by course providers, based upon guidance provided by the regulator.


In conjunction with the Department of Health, the PSNI will now work towards a further public consultation on the necessary legislative changes.

Dr Jim Livingstone, president of the PSNI, said: “The Department of Health has set a clear direction which will see pharmacist independent prescribers becoming increasingly important in the delivery of pharmacy services in Northern Ireland. Our role is to protect the public, but we are clear that our regulatory objective should not be an unnecessary barrier to the development of the profession and enhanced services being provided to the public."

The council’s recent public consultation outlined proposals on changes to the entry requirements for standalone independent prescribing courses and annotation as an IP on the register. The proposals sought to strike a right balance between protecting the public, whilst not placing disproportionate regulatory barriers in the way of developing services.

“I am pleased that our proposals were broadly supported,” Dr Livingstone said, adding: “Removing the two-year period before being annotated on the Register is necessary to deliver wider reforms to pharmacy education. We will continue to work with the Department of Health, to move towards a public consultation on the necessary legislative changes.

“We acknowledge the feedback received, that some further clarification and guidance is required in certain areas, and we have committed to working with our colleagues in the GPhC to develop guidance for course providers and others.

“We are also committed to exploring what additional support might be needed for independent prescribers in relation to post-registration education and professional development. We will take this work on as part of our partnership with the GPhC on the UK wide post-registration assurance of practise group. Ensuring that there is appropriate engagement and involvement with local stakeholders.

“We had several excellent responses to this consultation, which raised important issues. A number of these issues related to the wider education reform agenda and are outside the immediate responsibility of the Regulator. We have, however, committed to presenting our consultation report to the Education Reform Implementation Group, which is progressing these wider reforms in Northern Ireland.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less